Pulmonary Embolism and Thrombosis Clinical Trial
Official title:
Study of the OPTtimum Duration of Acoustic Pulse ThromboLYSis ProcEdure in the Treatment of Acute Submassive Pulmonary Embolism
The objective is to determine the optimum dose of thrombolytic and duration of the ultrasound procedure (together defined as the APT Procedure) as a treatment for acute submassive pulmonary embolism (PE). Symptomatic submassive PE are participants with acute (less than or equal to [≤]14 days) PE with normal systemic arterial blood pressure (greater than [>] 90 mmHg) and evidence of RV dysfunction (right ventricular to left ventricular diameter ratio, that is; RV/LV ratio greater than or equal to [≥] 0.9). Participants with submassive PE will be randomized to one of four APT treatment groups: ultrasound of 2 and 6 hours (hrs) with r-tPA 2 milligrams (mg)/hr/catheter and ultrasound 4 and 6 hours with r-tPA, 1 mg/hr/catheter. On 08 June 2016, randomization into treatment group 4 (APT/6 hours-r-tPA/2 mg/hr/catheter) was closed following a reported intracranial hemorrhage (ICH) and death in a study participant in this arm.
This study is designed to investigate the lowest recombinant tissue plasminogen activator (r-tPA) dose-ultrasound treatment time required to achieve the same reductions in thrombus burden and associated improvement in physiologic parameters demonstrated in ULTIMA (EKOS 08 [NCT01166997]) and SEATTLE II (EKOS 09 [NCT01513759]). Results of this study are intended to inform the study design for further studies of the Acoustic Pulse Thrombolysis (APT) Procedure. Analysis of the first 100 evaluable participants in the United States study suggested a degree of equipoise between treatment groups 1, 2 and 3 of the protocol and therefore the sample size has been extended and additional sites in the United Kingdom (UK) National Health Service included, with a view to adding to the findings of the OPTALYSE study from sites in the UK and increasing the number of participants treated by treatment protocol. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06348459 -
Registry of Catheter Intervention in Pulmonary Embolism
|
||
| Recruiting |
NCT03450304 -
Lung Perfusion Measured With Dual-Energy CT in Patients With Chronic Thromboembolic Pulmonary Hypertension: Comparative Study With Right Heart Catheterization and V/Q
|
N/A | |
| Not yet recruiting |
NCT06232551 -
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
|
N/A | |
| Completed |
NCT03426124 -
An International Pulmonary Embolism Registry Using EKOS
|
||
| Recruiting |
NCT06051032 -
Compative Study of PE in Thrombosed AVF After Balloon Thrombectomy vs. Thromboaspiration.
|
N/A | |
| Recruiting |
NCT05098769 -
A Predictive Tool for Predicting Adverse Outcomes in Acute Pulmonary Embolism Patients Using CTPA.
|
||
| Enrolling by invitation |
NCT04855370 -
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PE
|
N/A | |
| Recruiting |
NCT05482269 -
Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography
|
||
| Active, not recruiting |
NCT05481242 -
An Observational Study About Adverse Outcomes in Acute Pulmonary Embolism Patients
|
||
| Active, not recruiting |
NCT04632641 -
Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial
|
N/A | |
| Recruiting |
NCT03101384 -
Influence of Diagnostic Errors on the Prognosis of Acute Pulmonary Embolism
|
N/A | |
| Completed |
NCT04374617 -
Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19
|